Korean peptide-drug developer with a GLP-1/glucagon obesity and MASH pipeline, several candidates licensed to global partners.
Korean peptide-drug developer with a GLP-1/glucagon obesity and MASH pipeline, several candidates licensed to global partners.
Earns little from sales of its own; its value comes from licensing peptide candidates to bigger partners for upfront and milestone payments, and from equity stakes in those partners, notably Metsera, a US obesity-drug developer built partly on its licensed assets.
Moat: narrow (IP / patents). Peptide-delivery platform behind several GLP-1 obesity candidates already licensed to global partners.
Headquarters: Seoul, South Korea · Founded: 2014 · Employees: 22
Size D&D Pharmatech (347850.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.22B, the 209th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩35,800 on 18 Nov 2026.
Performance Over six months the shares fell 48.6%, against -20.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 76.8% over the last twelve months (peer median +7.6%); the operating margin is -2,324.3% (peer median -2.1%).
Valuation It trades at 818.8× enterprise value to sales against a peer median of 8.6× (most expensive of 18).
Capital Return on invested capital runs 46.5 points below its cost of capital (7.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.94B | ₩4.30B | ₩11.4B | ₩18.7B | ₩611M |
| Revenue growth | — | -62% | -39% | +2,959% | — |
| Gross profit | -₩3.77B | -₩1.23B | ₩5.91B | ₩14.2B | -₩13.1B |
| EBITDA | -₩39.3B | -₩28.5B | -₩19.5B | -₩9.06B | -₩54.9B |
| Net income | -₩32.9B | -₩23.6B | -₩28.6B | ₩3.93B | -₩136B |
| Free cash flow | -₩26.9B | -₩21.2B | -₩22.2B | -₩9.16B | -₩53.8B |
| Capital expenditure | ₩206M | ₩64.4M | ₩416M | ₩45.2M | ₩719M |
| Total debt | ₩118B | ₩6.24B | ₩9.78B | ₩8.13B | ₩27.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| D&D Pharmatech 347850.KS | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 347850.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.8% | -5.4% | 6th lowest of 21 |
| 6-month return | -48.6% | -20.6% | 3rd lowest of 21 |
| Distance from 52-week high | -69.3% | -41.7% | 2nd lowest of 21 |
| Revenue growth (TTM) | -76.8% | +7.6% | lowest of 18 |
| Operating margin | -2,324.3% | -2.1% | lowest of 18 |
| EV / Sales | 818.8× | 8.6× | most expensive of 18 |
| ROIC minus cost of capital | -46.5 pp | -6.1 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |